U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07136142) titled 'A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors' on Aug. 14.
Brief Summary: This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Malignant Solid Tumor
Intervention:
DRUG: FH-006 for Injection
FH-006 for injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....